icon-folder.gif   Conference Reports for NATAP  
  EASL 2024
June 5-8, Milan, Italy
Back grey_arrow_rt.gif
Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of the SIMPLIFY study
  EASL 2024 June 5-8 Milan Italy
Brian Conway1,2, Rossitta Yung1, Shawn Sharma1, Shana Yi1, Saina Beitari1. 1Vancouver Infectious Diseases Centre, Vancouver, Canada; 2Simon Fraser University, Burnaby, Canada